Gentium S.p.A. (Nasdaq: GENT) has requested a re-examination of the negative opinion adopted, by the European Medicines Agency's ("EMA") Committee ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE